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Recombination is an important driver in the evolution of virus-
es and thus is key to understanding viral epidemics and im-
proving strategies to prevent future outbreaks. Characteriza-
tion of rare recombinant subpopulations remains technically
challenging because of artifacts such as artificial recombinants,
known as chimeras, and amplification bias. To overcome this,
we have developed a high-throughput microfluidic technique
with a second verification step in order to amplify and se-
quence single recombinant viruses with high fidelity in picoli-
ter drops. We obtained the first artifact-free estimate of in vitro
recombination rate between murine norovirus strains MNV-1
and WU20 co-infecting a cell (Prec=3.3Õ10
¢42Õ10¢5) for
a 1205 nt region. Our approach represents a time- and cost-ef-
fective improvement over current methods, and can be adapt-
ed for genomic studies requiring artifact- and bias-free selec-
tive amplification, such as microbial pathogens, or rare cancer
cells.
Viruses pose a continuing threat to public health due to vari-
ous compounding factors, including a lack of effective treat-
ment, their rapid evolution, and the difficulty of characterizing
rare but potentially lethal strains.[1] Although recombinant mu-
tations are very infrequent, they have the potential to generate
dangerous, virulent strains, because the large-scale exchange
of genetic material can provide adaptations to escape immune
systems and resist treatment.[2] To more effectively combat
such lethal adaptations a better understanding of viral recom-
bination is required; however, current genomic sequencing
techniques involve amplification artifacts that obscure rare mu-
tations, and amplification bias complicates determining their
frequencies of occurrence.[3]
The major limitations for studying ribonucleic acid (RNA)
viral recombinants arise from the unavoidable genomic am-
plification step preceding the sequencing. When amplifying
rare recombinant templates in the presence of their parental
genomes, template switching can occur during reverse tran-
scription (RT) and PCR, thereby resulting in a concatenation of
two parental fragments. These artificial recombinants are
known as chimeras, and they are indistinguishable from true
biological recombinants (see Figure S1 in the Supporting Infor-
mation).[4] Chimeras can be avoided in emulsion PCR[5] by dilut-
ing the template so that drops contain at most a single tem-
plate (Table S1). However, emulsion PCR cannot overcome am-
plification bias and sequencing bias, which prevent sequencing
methods from quantifying recombinant subpopulations.[6] To
overcome counting bias, on-chip digital PCR[7] may be used to
count the number of true recombinants in a sample; however,
digital PCR is limited in the number of samples it can test and
does not have the capability to retrieve the content of ampli-
fied samples for sequencing (Table S1). Thus, a method that
can both count and sequence rare recombinants will improve
our understanding of viral recombination, thereby leading to
better antiviral drugs and vaccines.
Drop-based microfluidics (DBM) is a rapidly emerging tech-
nique whereby micron-sized aqueous drops immersed in an
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inert carrier oil are used as vessels for biological experiments.[8]
The drops are surrounded by surfactants carefully chosen to
prevent drop coalescence or surface adsorption of biological
molecules. Individual drops can be filled, steered, split, com-
bined, detected, and sorted in a microfluidic device at thou-
sands per second,[9] and their content is easily retrieved for
downstream analysis by separating the emulsion. The small
volume of these drops (~10 pL) is ideal for isolating single
molecules and assaying them with minimal background noise.
Hence DBM is ideal for developing a platform to amplify single
templates for both counting and downstream sequencing.
Here we developed a DBM technique that addresses the lim-
itations of current assays for characterizing and quantifying
rare genomes: single templates are isolated, individually ampli-
fied in drops, and then placed in microwells for processing. By
detecting, sorting, and consensus sequencing the amplicons,
we unambiguously determined both recombination frequency
and loci (Figure 1A). We demonstrate our technique by accu-
rate characterization of recombinant progeny from two RNA
murine norovirus (MNV) strains, MNV-1 and WU20, by co-infect-
ing a murine RAW 264.7 macrophage culture. This platform de-
creases the artifacts produced during RT, PCR amplification,
and sequencing to an arbitrarily low value.
To determine the concentration of the parental strains, we
co-encapsulated viral templates with Taqman probe (Life Tech-
nologies) in 8.25 pL drops and performed off-chip amplifica-
tion. This probe fluoresces only in the presence of viral tem-
plates (bright and dark drops in Figure 1C). We injected the
drops into a reading and sorting device (Figure 1A4), and ob-
tained distributions of size and intensity (Figure 2A). The aver-
age number of templates per drop (l) decreases with the dilu-
tion factor (X) according to l=cV/X, where c is the stock con-
centration and V is the volume of the drop. The number of
templates in any drop (n) follows a Poisson distribution (pn=
lne¢l/n ! ).[10] As l approaches 0, this distribution is binary be-
cause the probability of a drop containing multiple templates
is negligible. Accordingly, l approaches the ratio of bright
drops (which contain one template) to dark drops (no tem-
plate): l=N+/N¢. The data from the dilution series fit this
linear relationship well, and we obtained viral stock concentra-
Figure 1. Method overview. A) Schematic of experimental flow. 1) Viral recombinants are generated by co-infecting a RAW 264.7 cell culture with two MNV pa-
rental strains, MNV-1 and WU20; 2) Single viral genomes from cell lysate are mixed with a one-step RT-PCR solution and a DNA-intercalating dye; viral solution
is injected into a microfluidic drop-maker device; the oil streams then pinch off this viral solution for encapsulation in picoliter water-in-oil drops. 3) Collection
of the generated drops and thermocycling off-chip to amplify the recombination fragments. 4) Re-injection of drops into a microfluidic fluorescent drop
reader and sorter ; drops containing amplicons from the recombinant genomes (bright) are sorted. 5) Distribution of sorted bright drops into a 96-well plate.
6) Second-round PCR, extraction of amplicons of the correct length from the gel, and submission to Sanger sequencing. 7) The region of template switching
between parental genomes is determined by comparing the recovered sequence against the two reference genomes. B) Image of the microfluidic drop-
maker device. Two oil streams (O) pinch off the flowing viral solution (W), for encapsulation in picoliter water-in-oil drops (see also Figure S2). C) Fluorescence
image of drops after RT-PCR (inset: distribution of average fluorescence of each drop). D) Microfluidic fluorescent drop reader and sorter : electrodes are black,
laser spot is visible above the triangle mark. E) Gel electrophoresis of the amplicons from nine wells of the plate. Dashed line marks the expected amplicon
length (1205 bp). Amplicons of the correct length are extracted from the gel, and sent for Sanger sequencing.




10 genome copies per
mL (Figure 2B). Assuming a conversion factor of 1 PFU
(plaque-forming unit) per 100 viral genomes,[11] these concen-
trations are consistent with their infectivity titers (108 and 5Õ
108 PFUmL¢1, respectively).
We modified the above assay to determine the concentra-
tion of recombinants resulting from a macrophage cell-culture
co-infected with a mixture of both parental viruses, each with
a multiplicity of infection of 2. We use a one-step differential
RT-PCR cocktail[12] where each of the two primers is specific to
only one parental virus, in order to selectively amplify those
recombinants where template switching occurs in a selected
1205 bp region (Figure 3A; the top row of the gels confirms
that our cocktail amplified recombinants from the co-infection
without amplifying parental viruses in the viral mixture). For
our drop-based assay, the differential RT-PCR cocktail was co-
encapsulated with viral templates, and in-drop RT-PCR was
performed off-chip. In order to register amplicons, the cocktail
was supplemented with a DNA-intercalating dye, EvaGreen
(Biotium, Hayward, CA). We observed a broad distribution of
fluorescent drops, as expected when using a non-specific DNA
probe that registers both specific and non-specific target am-
plification (Figure 3B).
To increase the fidelity of our recombinant assay and ex-
clude false bright drops containing non-specific amplicons we
used a gel-verification procedure. Drops whose fluorescence
exceeded the threshold (F0=9.5; Figure 3B) were sorted in
a microfluidic device. The sorted drops were mixed with a suffi-
cient volume of buffer drops and distributed into many micro-
wells, such that at most one fluorescent drop was in each well.
A second round of differential in-well PCR was performed to
produce enough amplicons for gel electrophoresis, in order to
select drops containing amplicons of the right length (Fig-
ure 1E). The fluorescence threshold for sorting was set suffi-
ciently low to minimize loss of drops containing recombinants
(absence of a visible target band for drops with F<F0 ; Fig-
ure 3A, lower gels). Discarding recombinants of the wrong
length is justified because only potentially viable viruses are
considered;[13] however, amplicons of the right length are not
guaranteed to be true recombinants as they could be the
result of in-drop chimera generation.
Because in-drop chimera generation requires the presence
of multiple templates in the same drop, chimera generation
can be sufficiently repressed by diluting the template such
that the probability of any drop containing multiple templates
is negligible. We assayed a dilution series of a recombinant-
free mixture of both parental viruses, where target amplicons
can only result from in-drop chimera generation. For l0.3,
the fraction of gel-verified drops exhibits a quadratic trend,
Rchimera/l2, which is expected in the limit of small l, and is
shown by the filled blue squares and solid blue line in Fig-
ure 3C. We found no chimera drops for l=0.02 and 0.1, thus
establishing a safe range for chimera-free RT-PCR.
We determined the recombination frequency (the fraction of
recombinant genomes produced in one virus replication cycle)
in co-infected cells from a dilution series experiment with
a two-step recombinant assay. To estimate the recombinant
frequency we made two assumptions: the viral yield of the in-
fection far exceeds that of the initial inoculum, and almost all
of the cells are infected by both strains due to the high viral
loading. The recombination frequency (Prec) is thus the ratio of
the fraction of recombinant drops (Rrec) to the concentration of
parental virus, l (solid triangles in Figure 3C). To correct for
chimeras, we estimated the chimera frequency (Rchimera) from
the ratio of the fraction of gel-verified chimera drops (blue
squares in Figure 3C) to that of drops containing both parental
viruses ((1¢e¢(l/2))2) and obtained Pchimera=Rchimera/(1¢e¢(l/2))2=
1.2Õ10¢41Õ10¢5 (squares in Figure 3D). Accordingly the cor-
rected recombinant frequency is Prec= (Rrec¢Rchimera)/l=3.3Õ
10¢42Õ10¢5 (triangles in Figure 3D).
For a detailed analysis of recombinants we used Sanger se-
quencing with amplicons from nine gel-verified drops isolated
in microwells ; we obtained unambiguous traces, similar to
Figure 2. Quantification of the viral concentration of a MNV-1 stock. A) Heat
map showing the peak and width of fluorescence pulses from drops passing
through the laser beam of the microfluidic drop sorter. Drops with fluores-
cent peaks exceeding F0 (a) contain viral RNA. Right: distribution of the
peak fluorescence, where N+ and N¢ are the number of bright and dark
drops, respectively (threshold F0). B) Dependence of the fraction of bright
to dark drops (N+/N¢) on the dilution factor X. The concentration of
plaque-forming units (PFUmL¢1) is based on the initial stock concentration
(108 PFUmL¢1) and the concentration of MNV-1 genomes, N+/N¢/V, where V
is the drop volume (8.25 pL). A linear fit provides both the stock concentra-
tion of MNV-1 genomes (cMNV-1) and the ratio of genomes to PFU in the
stock.
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those for clone-based sequencing.[14,15] The sequences align
with WU20 genome at the 5’-end, and with MNV-1 at the 3’-
end; in between is the region of recombination
where template switching occurred. We identified
four unique regions in the sequenced drops (Fig-
ure S3). For example, the region of recombination of
Drop-1 spans nucleotides 4950–4968 and for Drop-9
it spans nucleotides 5240–5255 (Figure 4A and B). In-
terestingly, Drop-9 also includes a synonymous trans-
version at nucleotide 5221. Using this method, the
first recombinant (from Drop-1 sequence) was also
detected from in vivo samples by examining the
feces of mice that were co-infected with both paren-
tal strains.[12]
Our drop-based microfluidics technique combines
two novel steps to achieve bias- and artifact-free
characterization of rare RNA recombinants in the
presence of a large background of genomic material.
Single-step in-drop differential RT-PCR faithfully repli-
cates low-abundant target templates with negligible
chimera generation. Subsequent screening isolates
single drops containing recombinant amplicons for consensus
sequencing to provide bias-free genomic data. To our knowl-
Figure 3. Detection of recombinant viruses. A) Top: primer design for amplifying recombinants where template switching occurs (between bp 4722 and
5879). Middle: gel electrophoresis of bulk RT-PCR of lysates from the co-infected cell culture and the parental stock solutions (MNV-1, WU20). M: DNA ladder.
Bottom: gel electrophoresis of unsorted drops (pre-sorting), 500 bright drops with F>F0 and the remaining ~350000 drops with F<F0. B) Heat map showing
the peak and width of fluorescence pulses. The threshold for sorting is indicated by the dashed line. Right: distribution of the peak fluorescence of all pulses
detected. N+ : bright drops with F>F0 ; N¢ : remaining dark drops (parental virus concentration, l=1). C) Dependence of the fraction of bright and gel-verified
bright drops (N+/N¢) on the parental virus concentration (l) for both the lysate from co-infected cell culture and from a mixture of parental viral genomes.
D) Dependence of in-drop chimera (blue) and recombinant (red) frequency on the parental virus concentration.
Figure 4. Two recombinant sequences obtained by Sanger sequencing. Recombination
regions (gray background) exhibit template switching. The preceding WU20 parental
sequence is highlighted with a black background; the downstream MNV-1 parental
sequence is marked with a red background.
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edge, this is the first use of in-drop single-step RT-PCR with
a non-specific fluorescent probe; this is essential for assays
such as our search for recombinants where the target se-
quence is unknown. The continuous isolation of single tem-
plates for amplification, detection, and sequencings represents
an improvement over all methods for characterizing rare re-
combinant templates (Table S1) and provides detailed informa-
tion on both the frequency and diversity of recombinants.[15, 16]
Moreover, our technique can be adapted for studies of non-
specific rare genomic events, such as lateral gene transfer in
bacteria, homologous recombination in parasites, and V(D)J re-
combination in the mammalian immune system.[17]
Experimental Section
Experimental details can be found in the Supporting Information.
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